Merck's Hepatitis C Drug Wins Approval in Europe
May 23, 2011
After an accelerated review, the European Medicines Agency's Committee for Medicinal Products for Human Use has endorsed Victrelis (boceprevir), Merck's new hepatitis C treatment, and recommended that the European Commission grant marketing approval. The committee said Victrelis should be used in combination with interferon-based treatment in untreated patients with chronic hepatitis C, as well as in patients who had failed on treatment. The action came just a week after the drug was approved by the US Food and Drug Administration.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)